TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15695748

Group type: EXPERIMENTAL
Intervention: Simulator group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pain group
Number of subjects: 60
Study: 12368782

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine infusion for 48 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline infusion for 48 hours (placebo)
Number of subjects: 26
Study: 10211628

Group type: EXPERIMENTAL
Intervention: Oral 5-aminolevulinic acid (ALA) administration to normal volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral 5-aminolevulinic acid (ALA) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with ALAD deficiency porphyria and acute lead intoxication
Number of subjects: 0
Study: 8585739

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (5 days)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (10 days)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (10 days)
Number of subjects: 537
Study: 2715472

Group type: EXPERIMENTAL
Intervention: Fluorethylenepropylene (Teflon) (FEP) with s.f.e. of 20 erg/cm2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Parafilm (PAR) with s.f.e. of 26 erg/cm2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cellulose acetate (CA) with s.f.e. of 57 erg/cm2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enamel (E) with s.f.e. of 88 erg/cm2
Number of subjects: 12
Study: 64133

Group type: EXPERIMENTAL
Intervention: Celestin tube intubation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Procter-Livingstone tube intubation
Number of subjects: 62
Study: 6123836

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg every 8 h for three days postoperatively)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (every 8 h for three days postoperatively)
Number of subjects: 90
Study: 31447077

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) + Abiraterone acetate and prednisolone (AAP)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 901
Study: 28118996

Group type: EXPERIMENTAL
Intervention: Mel4 coated contact lenses
Number of subjects: 0
Study: 27938405

Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits (study group A - psychosocial rehabilitation)
Number of subjects: 14847

Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention with outreach visits (study group B - physical rehabilitation)
Number of subjects: 14847

Group type: EXPERIMENTAL
Intervention: Web-based audit and feedback intervention
Number of subjects: 14847
Study: 23895201

Group type: EXPERIMENTAL
Intervention: Integrated school-parent-worksite program that targeted healthy home food environments and energy balance self-monitoring
Number of subjects: 38

Group type: COMPARATOR
Intervention: Identical school-based program without worksite support
Number of subjects: 38
Study: 22761074

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 7
Study: 19331702

Group type: EXPERIMENTAL
Intervention: Prebiotic-containing starter formula supplemented with Lactobacillus paracasei ssp. paracasei and Bifidobacterium animalis ssp. lactis
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (same formula without probiotics)
Number of subjects: 126
Study: 17606474

Group type: EXPERIMENTAL
Intervention: Dietary 5-HT stimulation (tryptophan-rich alpha-lactalbumin, 4.8 g/100 g TRP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo protein (1.4 g/100 g TRP)
Number of subjects: 37
Study: 15337807

Group type: EXPERIMENTAL
Intervention: Psychological intervention (group sessions, one session per week for 4 months)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 227
Study: 12215311

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone therapy
Number of subjects: 0
Study: 9844983

Group type: EXPERIMENTAL
Intervention: Children and adolescents with autism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonautistic mentally retarded individuals
Number of subjects: 0
Study: 7744517

Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 87

Group type: COMPARATOR
Intervention: Polyacrylonitril membrane
Number of subjects: 87
Study: 2735740

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2098

Group type: EXPERIMENTAL
Intervention: Lactulose (24-day course)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lactulose (16-day course)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 1

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 30997784

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 40
Study: 28931220

Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimens
Number of subjects: 1833
Study: 25728808

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) via colonoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times a day for 3 days, followed by 125-500 mg/day every 2-3 days for at least 3 weeks)
Number of subjects: 20
Study: 23380105

Group type: EXPERIMENTAL
Intervention: Intravenous valproic acid (iVPA) 400 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular metoclopramide + subcutaneous sumatriptan (10 mg + 6 mg)
Number of subjects: 60
Study: 20880552

Group type: EXPERIMENTAL
Intervention: Pexelizumab
Number of subjects: 7353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7353
Study: 19391535

Group type: EXPERIMENTAL
Intervention: Acupuncture, moving cupping, blood‐letting puncture
Number of subjects: 176

Group type: COMPARATOR
Intervention: Medication (oral administration of Vit E and Vit C)
Number of subjects: 176
Study: 16805717

Group type: EXPERIMENTAL
Intervention: Antidiabetic treatments (e.g., thiazolidinediones)
Number of subjects: 0
Study: 14702242

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 111

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 111

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 111
Study: 10776514

Group type: COMPARATOR
Intervention: Humoral immunity assessment using SRID method for IgG, IgM, and IgA levels.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cell mediated immunity assessment measuring total T cells, Th cells, Ts cells, and Th:Ts cell ratio.
Number of subjects: 0
Study: 8801162

Group type: EXPERIMENTAL
Intervention: N-(4-hydroxyphenyl) retinamide (4HPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoyl β-glucuronide (RAG)
Number of subjects: 0
Study: 1642910

Group type: EXPERIMENTAL
Intervention: Inguinal field block with lignocaine before operation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inguinal field block with lignocaine after operation
Number of subjects: 32
Study: 6383741

Group type: EXPERIMENTAL
Intervention: Lorcainide (100 mg twice daily or three times daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Quinidine gluconate (324 mg three times daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 26
Study: 30040032

Group type: EXPERIMENTAL
Intervention: Individualized corrective exercises performed 3 times per week for 4 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard warm-up drills as part of morning physical training
Number of subjects: 44
Study: 29575941

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 12 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab monthly for 4 months followed by pro re nata injections
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 12 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab monthly for 4 months followed by pro re nata injections
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose ranibizumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional-dose ranibizumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 1 (vascularized serous pigment epithelial detachment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 2 (fibrovascular pigment epithelial detachment)
Number of subjects: 36
Study: 27245056

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 49

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 49
Study: 24477817

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol plus NAC
Number of subjects: 0
Study: 24188942

Group type: EXPERIMENTAL
Intervention: Neck flexion with lateral pressure
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lifting of the larynx
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 19834507

Group type: EXPERIMENTAL
Intervention: Topical Cyclosporine A (CsA) and artificial tear-drop treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Topical artificial tear-drop treatment
Number of subjects: 42
Study: 18277888

Group type: EXPERIMENTAL
Intervention: Hanaro uncovered metal stent
Number of subjects: 92

Group type: COMPARATOR
Intervention: Luminex uncovered metal stent
Number of subjects: 92
Study: 15764758

Group type: EXPERIMENTAL
Intervention: Permanent RV pacing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Back-up pacing
Number of subjects: 17
Study: 12970812

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg IM or IV within 72 hours of delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg IM or IV within 72 hours of delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg at 28 weeks' gestation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg at 28 weeks and 34 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after miscarriage or abortion after 12 weeks' gestation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg before 12 weeks' gestation after miscarriage or abortion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after ectopic pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after chorionic villous sampling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 300 microg after cordocentesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-D Ig 120 microg or 300 microg for quantitating FMH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing for FMH after events associated with placental trauma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal or written informed consent prior to administration of Rh immune globulin
Number of subjects: 0
Study: 11077903

Group type: EXPERIMENTAL
Intervention: Screening group (PSA, DRE, TRUS, biopsy on indication)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Both groups (refusers vs attenders)
Number of subjects: 626
Study: 8898425

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/hepatitis B vaccine
Number of subjects: 156
Study: 1893686

Group type: EXPERIMENTAL
Intervention: MCI/MI (100 ppm)
Number of subjects: 4713

Group type: EXPERIMENTAL
Intervention: MCI/MI-preserved product
Number of subjects: 4713

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 4713

Group type: EXPERIMENTAL
Intervention: Retesting of MCI/MI sensitized patients
Number of subjects: 4713
Study: 6402951

Group type: EXPERIMENTAL
Intervention: Oxygen flow of 8 litres/minute delivered via Magill or Bain breathing attachment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Magill breathing system with reservoir bag filled with oxygen prior to application
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Gas-tight fits of face masks on patients
Number of subjects: 32
Study: 31952280

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and lactose hydrate (placebo of MgO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and Magnesium Oxide (MgO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo of Lactobacillus reuteri DSM 17938 and Magnesium Oxide (MgO)
Number of subjects: 60
Study: 30995673

Group type: EXPERIMENTAL
Intervention: CPAP at +5 cm H2O
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 49
Study: 28298878

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) oxygen therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy (COG)
Number of subjects: 110
Study: 27765582

Group type: EXPERIMENTAL
Intervention: TXA Dose I ‐ 1 g bolus followed by 1 g infusion over 8 h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TXA Dose II ‐ 1 g bolus followed by 10 mg/kg/hr until the end of surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 18
Study: 24311515

Group type: EXPERIMENTAL
Intervention: 5 g EPA-rich lipid for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control lipid for 12 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EPA supplementation
Number of subjects: 79
Study: 22203134

Group type: EXPERIMENTAL
Intervention: PGE(1) group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 19370408

Group type: EXPERIMENTAL
Intervention: Age and past sexual behavior as precursors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control variables (age and past behavior)
Number of subjects: 0
Study: 18589448

Group type: EXPERIMENTAL
Intervention: Insulin glargine (n = 76)
Number of subjects: 175

Group type: COMPARATOR
Intervention: NPH/Lente (n = 81)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 175

Group type: COMPARATOR
Intervention: NPH/Lente
Number of subjects: 175
Study: 15800958

Group type: EXPERIMENTAL
Intervention: Pylorus-preserving resection
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard Whipple operation
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 130
Study: 12357140

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 8

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 8
Study: 10491451

Group type: EXPERIMENTAL
Intervention: High dose fluticasone propionate (2000 microg/day, FP2000)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral prednisolone (30 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lower dose fluticasone propionate (500 microg/day, FP500)
Number of subjects: 120
Study: 8367920

Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg s.c. once every four weeks) and flutamide (250 mg three times daily)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Bilateral orchiectomy
Number of subjects: 327
Study: 2425334

Group type: EXPERIMENTAL
Intervention: Nurse home visitation
Number of subjects: 0
Study: 31578169

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg daily
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 29411272

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study: 26810904

Group type: EXPERIMENTAL
Intervention: Intermittent sciatic block (boluses on demand only)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Continuous sciatic block (continuous infusion)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups (Intermittent and Continuous)
Number of subjects: 140
Study: 25363150

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Various treatments including rituximab
Number of subjects: 64
Study: 23754611

Group type: COMPARATOR
Intervention: Control transurethral resection of the bladder (TURB) with standardized tumor documentation
Number of subjects: 167
Study: 21403017

Group type: COMPARATOR
Intervention: Placebo group of the DATATOP trial
Number of subjects: 157
Study: 19595163

Group type: EXPERIMENTAL
Intervention: Neuronal activity in the ventrolateral thalamus (Vop/Vim) in ET patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neuronal activity in the ventrolateral thalamus (Vop/Vim) in PD patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of MSFR levels in Vop/Vim between ET and PD patients
Number of subjects: 20
Study: 16494147

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous saline (control group)
Number of subjects: 44
Study: 15100716

Group type: EXPERIMENTAL
Intervention: High-fibre diet (HFD) with Nib meal frequency
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre diet (LFD) with Nib meal frequency
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre diet (LFD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fibre diet (HFD)
Number of subjects: 10
Study: 10934908

Group type: EXPERIMENTAL
Intervention: Recognition memory task using 'remember' (R) and 'know' (K) judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Principal component analysis of positive waveform elicited by test list words
Number of subjects: 0
Study: 9612877

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 8071050

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 190

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 190

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 190

Group type: COMPARATOR
Intervention: Comparators (iopamidol and iohexol)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Iopromide and Comparators
Number of subjects: 190
Study: 3338250

Group type: EXPERIMENTAL
Intervention: Passive upright tilting by 60 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive upright tilting by 20 degrees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of supine values and responses to tilting by 60 degrees across four age groups
Number of subjects: 0
Study: 31007142

Group type: EXPERIMENTAL
Intervention: Resolution of myofascial pain syndrome (MPS)
Number of subjects: 29
Study: 31358713

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 28
Study: 28459603

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) algorithm (CL1/CL2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open-loop (OL) conventional pump therapy (OL1/OL2)
Number of subjects: 20
Study: 25308195

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 52

Group type: COMPARATOR
Intervention: Theatre-based teaching
Number of subjects: 52
Study: 23786436

Group type: EXPERIMENTAL
Intervention: Trust in doctors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trust in hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trust in racial equity of treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitudes toward dialysis
Number of subjects: 0
Study: 21542109

Group type: EXPERIMENTAL
Intervention: Genous stent
Number of subjects: 193

Group type: COMPARATOR
Intervention: Taxus stent
Number of subjects: 193
Study: 18678610

Group type: EXPERIMENTAL
Intervention: Technosphere insulin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Technosphere powder (placebo)
Number of subjects: 126
Study: 16544213

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 11
Study: 14557959

Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg, single oral dose)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Levofloxacin (500 mg, single oral dose)
Number of subjects: 217
Study: 10928293

Group type: EXPERIMENTAL
Intervention: 50 mMol/day salt intake
Number of subjects: 55

Group type: COMPARATOR
Intervention: 150 mMol/day salt intake
Number of subjects: 55
Study: 8881323

Group type: EXPERIMENTAL
Intervention: Emphasis on item information during study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emphasis on associative information during study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast presentation rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow presentation rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High word concreteness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low word concreteness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High word frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low word frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measures of confidence and response latency
Number of subjects: 0
Study: 8097733

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms, subcutaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3710012

Group type: EXPERIMENTAL
Intervention: Clonidine (225 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (154 mmol/l)
Number of subjects: 12
Study: 31881621

Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 29990584

Group type: EXPERIMENTAL
Intervention: Short-term Mindfulness-Based Stress Reduction (MBSR) course (N=32)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Active control condition (N=35)
Number of subjects: 97
Study: 27916047

Group type: COMPARATOR
Intervention: 20 mg atorvastatin (standard group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin (intensive group)
Number of subjects: 120
Study: 24203849

Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (rPerC)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 443